Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Pfizer OTC, Moberg, Atrium, C&D, Wockhardt, Herbalife

This article was originally published in The Tan Sheet

Executive Summary

Pfizer expands European OTC business; Moberg expands in U.S. with Bayer brands; Atrium would go private in $1.1 billion deal; C&D not bearish on gummies; GMP warning for two Wockhardt facilities; and Belgian court: Herbalife not a pyramid scheme.

You may also be interested in...



Moberg Sustains Derma Drive, Acquires Prestige Brands' New Skin

The Swedish firm pays $40m for the PediaCare and Fiber Choice brands in addition to New Skin Liquid Bandages, which are available in spray and liquid delivery and are "the main profitability contributor in the acquired portfolio," says CEO Peter Wolpert.

Moberg Sustains Derma Drive, Acquires Prestige Brands' New Skin

The Swedish firm pays $40m for the PediaCare and Fiber Choice brands in addition to New Skin Liquid Bandages, which are available in spray and liquid delivery and are "the main profitability contributor in the acquired portfolio," says CEO Peter Wolpert.

Herbalife Pushes To Counter Pyramid Scheme Narrative

The multilevel marketer of weight-management shakes and other nutritionals says its independent distributor network, far from being a pyramid scheme, in fact is essential in helping people lose weight and adopt healthy lifestyles, according to Herbalife executives.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel